<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101841</url>
  </required_header>
  <id_info>
    <org_study_id>N30-004</org_study_id>
    <nct_id>NCT01101841</nct_id>
  </id_info>
  <brief_title>24-Week Efficacy &amp; Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms</brief_title>
  <official_title>A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for
      treatment of vasomotor symptoms (VMS) associated with menopause
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 24-week, multicenter, double-blind, randomized, placebo-controlled study of
      Brisdelle (paroxetine mesylate) Capsules 7.5 mg in subjects with moderate to severe
      postmenopausal VMS, defined as follows:

        1. Moderate VMS: Sensation of heat with sweating, able to continue activity

        2. Severe VMS: Sensation of heat with sweating, causing cessation of activity

      The study is comprised of a screening period, a run-in period, a baseline visit, and a
      double-blind treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects recorded the number of hot flashes per week using an electronic diary. The results reported are not hot flashes per week.
The results reported are:
Mean Baseline frequency of moderate to severe VMS
Mean change in frequency of moderate to severe VMS from baseline to Week 4
Mean change in frequency of moderate to severe VMS from baseline to Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Persistence of Benefit, Statistically Significant Difference in Having 50% or More Reduction Compared to Baseline at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>Persistence of treatment benefit to 24 weeks post treatment was assessed by using the following responder analysis. Responders were defined as those subjects who achieved ≥ 50% reduction from baseline in moderate to severe hot-flash frequency at Week 24; the percent change in hot flash frequency is calculated using the formula:
Percent reduction at week 24 = [(number of moderate to severe hot flash frequency at baseline - number of moderate to severe hot flash frequency at week 24) / number of moderate to severe hot flash frequency at baseline ]*100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI &lt;32 kg/m2, Week 4 and Week 12), Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Participants completed a electronic diary to report nightime awakenings. Subjects took study drug once daily at bedtime and they were instructed to complete daily hot flash and sleep diaries to record the number of hot flashes daily, the severity of each episode of hot flash and total number of awakenings due to hot flashes.
The diary data was used to evaluate and compare the treatment groups, on the change from baseline to Week 4 and Week 12, in the total number of awakenings due to hot flashes. The total number of awakenings due to hot flashes in the run-in period was used as baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI &lt;32 kg/m2, At Week 4 and Week 12), Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>The Greene Climacteric Scale (GCS) was used for this measurement. The scale has 21 questions and measures symptoms in 4 areas; these are psychological (anxiety and depression), physical, vasomotor, and libido.
The severity of the symptom was scored as: 0=none, 1=mild, 2=moderate, and 3=severe. Anxiety was determined by using the sum of scores 1 to 6, and depression was determined by using the sum of scores 7 to 11. Physical aspects were determined by using the sum of scores 12 to 18; vasomotor aspects were determined by using the sum of scores 19 to 20; and libido was determined by using the score for question 21.
The total GCS score ranges from &quot;0&quot; to &quot;63&quot; which is the sum of all the scores for the 21-symptom assessment questions in this scale. Each subject's total GCS score at baseline and at Week 4 and Week 12 were used to calculate change from baseline in these symptoms. The change from baseline is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Participants reported the number of hot flashes using an electronic diary. Participants who hd a ≥50% reduction in hot flash frequency were defined as responders. The percent of responders is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subject's overall improvement in VMS from Baseline assessed using the Numerical Rating Scale (NRS) The NRS is measured on a scale of 0 to 10 on how bothered the subject was by her VMS (0=not bothered at all and 10=very much bothered).
Responders: Subjects with NRS Score of 5 Or Less. Non-Responders: Subjects With NRS Score of Greater than Or Equal to 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score, Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>The Arizona Sexual Experiences Scale (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction.The sum of the scores for all 5 items was calculated at Week 4 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Interference of hot flashes was measured by using the hot flash-related daily interference scale (HFRDIS). The HFRDIS is a 10-item scale that measures the degree to which hot flashes interfere with 9 daily activities and the tenth item measures the degree to which hot flashes interfere with each of the other items. Subjects can score for each item on a scale from 0 to 10 where 0 = Do not interfere and a score of 10 = Completely interferes.
The measure being reported below is percentage of responders who had an improvement in HFRDIS score at Week 4 and Week 12 compared to baseline. A responder is defined as a subject who had an improvement in the HFRDIS score. An improvement is defined as a score ≤3 on each question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Proportion of NRS Responders: Subject's overall improvement in VMS from Baseline was assessed using the Numerical Rating Scale (NRS)
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Responders: Subjects Achieving a Score of &quot;Very Much Improved&quot; Or &quot;Much Improved&quot; Or &quot;Minimally Improved&quot;.
Non Responders: Subjects with a Score of &quot;No Change&quot; Or &quot;Minimally Worse&quot; Or &quot;Much Worse&quot; Or &quot;Very Much Worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Depression &amp; anxiety were measured by using the Hospital Anxiety &amp; Depression Scale (HADS).
The HADS was developed to assess anxiety &amp; depression. It is meant to differentiate symptoms of depression with those of anxiety.
Number of items: 14 (7 questions relating to anxiety; 7 questions relating to depression).
Responses are based on the relative frequency of symptoms over the past week, using a four point scale ranging from 0 (not at all) to 3 (very often indeed).
Responses are summed to provide separate scores for anxiety and depression symptomology with possible scores ranging from 0 to 21 for each scale.
The results presented below are the percentage of participants with abnormal HADS Scores for both Abnormal Anxiety &amp; Abnormal Depression at Week 4 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Mood</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Mood was measured by using the Profile of Mood States (POMS) questionnaire. The Profile of Moods States (POMS) is a 65-item multi-dimensional measure that provides a method of assessing transient, fluctuating active mood states. Key areas that are measured include: tension-anxiety, anger-hostility, fatigue-inertia, depression-dejection, vigor-activity, confusion-bewilderment. Responses to questions are scored with the following numerical values: Not at all = 1, A little = 2, Moderate = 3, Quite a bit = 4, Extremely = 5. A total score for a domain was obtained by summing the responses of individual items in the domain. The total POMS score can range from &quot;65&quot; to &quot;325.&quot; Each subject's total POMS score at baseline and at Week 4 and Week 12 were used to calculate the percent of participants with less disturbance in mood at Week 4 and Week 12 compared to baseline. The percent of participants with less disturbance in mood is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI Change From Baseline (kg/m2), Median</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
Assessment of the effect of Brisdelle compared with placebo on body mass index.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Brisdelle (paroxetine mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brisdelle (paroxetine mesylate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brisdelle (paroxetine mesylate)</intervention_name>
    <description>Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.</description>
    <arm_group_label>Brisdelle (paroxetine mesylate)</arm_group_label>
    <other_name>Former Names: Mesafem Capsules or</other_name>
    <other_name>LDMP (Low-Dose Mesylate salt of Paroxetine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.</description>
    <arm_group_label>Placebo capsules</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, &gt;40 years of age

          2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60
             moderate to severe hot flashes per week for at least 30 days prior

          3. Spontaneous amenorrhea for at least 12 consecutive months

          4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause

          5. Bilateral salpingo-oophorectomy &gt;6 weeks with or without hysterectomy

        Exclusion Criteria:

          1. BMI ≥ 40 kg/m²

          2. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or
             Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS

          3. History of self-injurious behavior

          4. History of clinical diagnosis of depression; or treatment for depression

          5. History of clinical diagnosis of borderline personality disorder

          6. Use of an investigational study medication within 30 days prior to screening or during
             the study

          7. Concurrent participation in another clinical trial or previous participation in this
             trial

          8. Family of investigational-site staff
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derrick R Havin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Spokane Women's Clinic Research, Spokane, WA 99207</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E Hedrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawthorne Medical Research, Inc., Winston-Salem, NC 27103</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel N Lederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altus Research, Lake Worth, FL 33461</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry S Seidman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia Clinical Research, LLC, Philadelphia, PA 19114</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James E Tomblin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawthorne Medical Research, Inc., Greensboro, NC 27408</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter A Zedler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Women's Center, Richmond, VA 23233</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D S Harnsberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chattanooga Medical Research, LLC, Chattanooga, TN 37404</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John A Hoekstra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research, Inc., Richmond, VA 23294</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Kroll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Clinical Research Center, Seattle, WA 98105</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashley Tunkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anchor Research Center, Naples, FL 34102</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Clinical Research, Rochester, NY 14609</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna DeSantis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Valley Family Physicians PLC, Chandler, AZ 85224</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Drosman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genesis Center For Clinical Research, San Diego, CA 92103</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mildred Farmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meridien Research, Brooksville, FL 34601</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Hurtado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Woman's Hospital of Texas Clinical Research Center, Houston, TX 77054</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Ob-Gyn Associates, LLC, Moorestown, NJ 08057</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tyrone Malloy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soapstone Center for Clinical Research, Decatur, GA 30034</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apex Research Institute, Santa Ana, CA 92705</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Strout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coastal Carolina Research Center, Mt. Pleasant, SC 29464</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Waldbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Downtown Women's Health Care, Denver, CO, 80218</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Zbella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Medical Research Group, LLC, Clearwater, FL 33759</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James R Dockery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montgomery Women's Health Associates, PC, Montgomery, AL 36116</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen C Blank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Vernon Clinical Research, LLC, Sandy Springs, GA 30328</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Aqua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visions Clinical Research, Boynton Beach, FL 33472</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saul R Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Research Services, LLC, Pittsburgh, PA 15206</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marvin Kalafer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Clinical Trial Center, LLC, Jenkintown, PA 19046</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Portman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbus Center for Women's Health Research, Columbus, Ohio 43213</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Swanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Clinic of Lincoln, PC, Lincoln, NE 68510</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Soufer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chase Medical Research, LLC, Waterbury, CT 06708</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ShaH R Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Associates, Inc., Nashville, TN 37203</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary K Neuffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC Clinical Research Center, LLC, Columbia, SC 29201</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Ackerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Clinical Trials, LLC, West Palm Beach, FL 33409</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montgomery Women's Health Associates, PC</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Family Physicians PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Center For Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research Institute</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anchor Research Center</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soapstone Center for Clinical Research</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinic of Lincoln, PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Ob-Gyn Associates, LLC</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Research</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Center for Women's Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Clinical Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services, LLC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Clinical Research Center, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Women's Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Spokane Women's Clinic Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.noven.com</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother. 2004 Sep;38(9):1482-99. Epub 2004 Aug 3. Review.</citation>
    <PMID>15292498</PMID>
  </reference>
  <reference>
    <citation>Kritz-Silverstein D, Goldani Von Mühlen D, Barrett-Connor E. Prevalence and clustering of menopausal symptoms in older women by hysterectomy and oophorectomy status. J Womens Health Gend Based Med. 2000 Sep;9(7):747-55.</citation>
    <PMID>11025867</PMID>
  </reference>
  <reference>
    <citation>Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006 May 3;295(17):2057-71. Review.</citation>
    <PMID>16670414</PMID>
  </reference>
  <reference>
    <citation>Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res. 1976;20(5):425-30.</citation>
    <PMID>1003364</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <results_first_submitted>July 16, 2013</results_first_submitted>
  <results_first_submitted_qc>March 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <disposition_first_submitted>February 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 24, 2012</disposition_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasomotor Symptoms</keyword>
  <keyword>Menopause</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Perimenopause</keyword>
  <keyword>Nonhormonal therapies</keyword>
  <keyword>Climacteric symptoms</keyword>
  <keyword>Mesafem</keyword>
  <keyword>Low-Dose Mesylate salt of Paroxetine (LDMP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>24-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules in subjects with moderate to severe postmenopausal vasomotor symptoms.
Locations: Medical Clinics</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
          <description>Experimental
Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsules</title>
          <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suicidality Tracking Scale</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
          <description>Experimental
Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Capsules</title>
          <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="285"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="570"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="5.47"/>
                    <measurement group_id="B2" value="54.5" spread="5.74"/>
                    <measurement group_id="B3" value="54.4" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.</title>
        <description>Subjects recorded the number of hot flashes per week using an electronic diary. The results reported are not hot flashes per week.
The results reported are:
Mean Baseline frequency of moderate to severe VMS
Mean change in frequency of moderate to severe VMS from baseline to Week 4
Mean change in frequency of moderate to severe VMS from baseline to Week 12</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.</title>
          <description>Subjects recorded the number of hot flashes per week using an electronic diary. The results reported are not hot flashes per week.
The results reported are:
Mean Baseline frequency of moderate to severe VMS
Mean change in frequency of moderate to severe VMS from baseline to Week 4
Mean change in frequency of moderate to severe VMS from baseline to Week 12</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot flashes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="3.86"/>
                    <measurement group_id="O2" value="10.90" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="4.02"/>
                    <measurement group_id="O2" value="-2.71" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="4.67"/>
                    <measurement group_id="O2" value="-3.94" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Week 4 frequency</p_value_desc>
            <method>Rank transformed ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Week 12 frequency</p_value_desc>
            <method>Rank transformed ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Persistence of Benefit, Statistically Significant Difference in Having 50% or More Reduction Compared to Baseline at Week 24.</title>
        <description>Persistence of treatment benefit to 24 weeks post treatment was assessed by using the following responder analysis. Responders were defined as those subjects who achieved ≥ 50% reduction from baseline in moderate to severe hot-flash frequency at Week 24; the percent change in hot flash frequency is calculated using the formula:
Percent reduction at week 24 = [(number of moderate to severe hot flash frequency at baseline – number of moderate to severe hot flash frequency at week 24) / number of moderate to severe hot flash frequency at baseline ]*100%.</description>
        <time_frame>Week 24</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Persistence of Benefit, Statistically Significant Difference in Having 50% or More Reduction Compared to Baseline at Week 24.</title>
          <description>Persistence of treatment benefit to 24 weeks post treatment was assessed by using the following responder analysis. Responders were defined as those subjects who achieved ≥ 50% reduction from baseline in moderate to severe hot-flash frequency at Week 24; the percent change in hot flash frequency is calculated using the formula:
Percent reduction at week 24 = [(number of moderate to severe hot flash frequency at baseline – number of moderate to severe hot flash frequency at week 24) / number of moderate to severe hot flash frequency at baseline ]*100%.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>percentage of total number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.54"/>
                    <measurement group_id="O2" value="36.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0066</p_value>
            <p_value_desc>Week 24 persistence of effect</p_value_desc>
            <method>Logit model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI &lt;32 kg/m2, Week 4 and Week 12), Median</title>
        <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI &lt;32 kg/m2, Week 4 and Week 12), Median</title>
          <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot flashes per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.50" lower_limit="-130" upper_limit="48.00"/>
                    <measurement group_id="O2" value="-18.0" lower_limit="-151" upper_limit="119.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.00" lower_limit="-150" upper_limit="119.0"/>
                    <measurement group_id="O2" value="-27.00" lower_limit="-168" upper_limit="127.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median</title>
        <description>Participants completed a electronic diary to report nightime awakenings. Subjects took study drug once daily at bedtime and they were instructed to complete daily hot flash and sleep diaries to record the number of hot flashes daily, the severity of each episode of hot flash and total number of awakenings due to hot flashes.
The diary data was used to evaluate and compare the treatment groups, on the change from baseline to Week 4 and Week 12, in the total number of awakenings due to hot flashes. The total number of awakenings due to hot flashes in the run-in period was used as baseline.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median</title>
          <description>Participants completed a electronic diary to report nightime awakenings. Subjects took study drug once daily at bedtime and they were instructed to complete daily hot flash and sleep diaries to record the number of hot flashes daily, the severity of each episode of hot flash and total number of awakenings due to hot flashes.
The diary data was used to evaluate and compare the treatment groups, on the change from baseline to Week 4 and Week 12, in the total number of awakenings due to hot flashes. The total number of awakenings due to hot flashes in the run-in period was used as baseline.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Awakenings</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.50" lower_limit="-78.1" upper_limit="46.00"/>
                    <measurement group_id="O2" value="-6.62" lower_limit="-47.0" upper_limit="34.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.15" lower_limit="-80.1" upper_limit="49.00"/>
                    <measurement group_id="O2" value="-8.67" lower_limit="-47.5" upper_limit="22.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</title>
        <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either MesaBrisdelle (paroxetine mesylate) Capsules fem or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</title>
          <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot flashes per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" lower_limit="-118" upper_limit="30.00"/>
                    <measurement group_id="O2" value="-17.0" lower_limit="-93" upper_limit="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.50" lower_limit="-124" upper_limit="38.00"/>
                    <measurement group_id="O2" value="-23.00" lower_limit="-93" upper_limit="57.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI &lt;32 kg/m2, At Week 4 and Week 12), Median</title>
        <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI &lt;32 kg/m2, At Week 4 and Week 12), Median</title>
          <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI &lt;32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot Flash Severity scores per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" lower_limit="-1.0" upper_limit="0.50"/>
                    <measurement group_id="O2" value="-0.004" lower_limit="-1.0" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" lower_limit="-1.0" upper_limit="0.89"/>
                    <measurement group_id="O2" value="-0.00" lower_limit="-1.0" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</title>
        <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median</title>
          <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
For the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.
Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot Flash Severity scores per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039" lower_limit="-0.94" upper_limit="0.81"/>
                    <measurement group_id="O2" value="-0.036" lower_limit="-0.56" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.052" lower_limit="-0.57" upper_limit="0.97"/>
                    <measurement group_id="O2" value="-0.051" lower_limit="-1.0" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median</title>
        <description>The Greene Climacteric Scale (GCS) was used for this measurement. The scale has 21 questions and measures symptoms in 4 areas; these are psychological (anxiety and depression), physical, vasomotor, and libido.
The severity of the symptom was scored as: 0=none, 1=mild, 2=moderate, and 3=severe. Anxiety was determined by using the sum of scores 1 to 6, and depression was determined by using the sum of scores 7 to 11. Physical aspects were determined by using the sum of scores 12 to 18; vasomotor aspects were determined by using the sum of scores 19 to 20; and libido was determined by using the score for question 21.
The total GCS score ranges from &quot;0&quot; to &quot;63&quot; which is the sum of all the scores for the 21-symptom assessment questions in this scale. Each subject’s total GCS score at baseline and at Week 4 and Week 12 were used to calculate change from baseline in these symptoms. The change from baseline is reported below.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median</title>
          <description>The Greene Climacteric Scale (GCS) was used for this measurement. The scale has 21 questions and measures symptoms in 4 areas; these are psychological (anxiety and depression), physical, vasomotor, and libido.
The severity of the symptom was scored as: 0=none, 1=mild, 2=moderate, and 3=severe. Anxiety was determined by using the sum of scores 1 to 6, and depression was determined by using the sum of scores 7 to 11. Physical aspects were determined by using the sum of scores 12 to 18; vasomotor aspects were determined by using the sum of scores 19 to 20; and libido was determined by using the score for question 21.
The total GCS score ranges from &quot;0&quot; to &quot;63&quot; which is the sum of all the scores for the 21-symptom assessment questions in this scale. Each subject’s total GCS score at baseline and at Week 4 and Week 12 were used to calculate change from baseline in these symptoms. The change from baseline is reported below.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" lower_limit="-36" upper_limit="16.00"/>
                    <measurement group_id="O2" value="-3.00" lower_limit="-37" upper_limit="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" lower_limit="-33" upper_limit="14.00"/>
                    <measurement group_id="O2" value="-3.00" lower_limit="-32" upper_limit="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders</title>
        <description>Participants reported the number of hot flashes using an electronic diary. Participants who hd a ≥50% reduction in hot flash frequency were defined as responders. The percent of responders is presented below.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders</title>
          <description>Participants reported the number of hot flashes using an electronic diary. Participants who hd a ≥50% reduction in hot flash frequency were defined as responders. The percent of responders is presented below.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56"/>
                    <measurement group_id="O2" value="25.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.30"/>
                    <measurement group_id="O2" value="33.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)</title>
        <description>Subject's overall improvement in VMS from Baseline assessed using the Numerical Rating Scale (NRS) The NRS is measured on a scale of 0 to 10 on how bothered the subject was by her VMS (0=not bothered at all and 10=very much bothered).
Responders: Subjects with NRS Score of 5 Or Less. Non-Responders: Subjects With NRS Score of Greater than Or Equal to 6.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)</title>
          <description>Subject's overall improvement in VMS from Baseline assessed using the Numerical Rating Scale (NRS) The NRS is measured on a scale of 0 to 10 on how bothered the subject was by her VMS (0=not bothered at all and 10=very much bothered).
Responders: Subjects with NRS Score of 5 Or Less. Non-Responders: Subjects With NRS Score of Greater than Or Equal to 6.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>percentage of total number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.48"/>
                    <measurement group_id="O2" value="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.62"/>
                    <measurement group_id="O2" value="37.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score, Median</title>
        <description>The Arizona Sexual Experiences Scale (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction.The sum of the scores for all 5 items was calculated at Week 4 and Week 12.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score, Median</title>
          <description>The Arizona Sexual Experiences Scale (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction.The sum of the scores for all 5 items was calculated at Week 4 and Week 12.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)</title>
        <description>Interference of hot flashes was measured by using the hot flash-related daily interference scale (HFRDIS). The HFRDIS is a 10-item scale that measures the degree to which hot flashes interfere with 9 daily activities and the tenth item measures the degree to which hot flashes interfere with each of the other items. Subjects can score for each item on a scale from 0 to 10 where 0 = Do not interfere and a score of 10 = Completely interferes.
The measure being reported below is percentage of responders who had an improvement in HFRDIS score at Week 4 and Week 12 compared to baseline. A responder is defined as a subject who had an improvement in the HFRDIS score. An improvement is defined as a score ≤3 on each question.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)</title>
          <description>Interference of hot flashes was measured by using the hot flash-related daily interference scale (HFRDIS). The HFRDIS is a 10-item scale that measures the degree to which hot flashes interfere with 9 daily activities and the tenth item measures the degree to which hot flashes interfere with each of the other items. Subjects can score for each item on a scale from 0 to 10 where 0 = Do not interfere and a score of 10 = Completely interferes.
The measure being reported below is percentage of responders who had an improvement in HFRDIS score at Week 4 and Week 12 compared to baseline. A responder is defined as a subject who had an improvement in the HFRDIS score. An improvement is defined as a score ≤3 on each question.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.03"/>
                    <measurement group_id="O2" value="30.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.89"/>
                    <measurement group_id="O2" value="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.</title>
        <description>Proportion of NRS Responders: Subject’s overall improvement in VMS from Baseline was assessed using the Numerical Rating Scale (NRS)
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Responders: Subjects Achieving a Score of “Very Much Improved” Or “Much Improved” Or “Minimally Improved”.
Non Responders: Subjects with a Score of “No Change” Or “Minimally Worse” Or “Much Worse” Or “Very Much Worse”.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.</title>
          <description>Proportion of NRS Responders: Subject’s overall improvement in VMS from Baseline was assessed using the Numerical Rating Scale (NRS)
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Responders: Subjects Achieving a Score of “Very Much Improved” Or “Much Improved” Or “Minimally Improved”.
Non Responders: Subjects with a Score of “No Change” Or “Minimally Worse” Or “Much Worse” Or “Very Much Worse”.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.88"/>
                    <measurement group_id="O2" value="53.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.88"/>
                    <measurement group_id="O2" value="59.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression</title>
        <description>Depression &amp; anxiety were measured by using the Hospital Anxiety &amp; Depression Scale (HADS).
The HADS was developed to assess anxiety &amp; depression. It is meant to differentiate symptoms of depression with those of anxiety.
Number of items: 14 (7 questions relating to anxiety; 7 questions relating to depression).
Responses are based on the relative frequency of symptoms over the past week, using a four point scale ranging from 0 (not at all) to 3 (very often indeed).
Responses are summed to provide separate scores for anxiety and depression symptomology with possible scores ranging from 0 to 21 for each scale.
The results presented below are the percentage of participants with abnormal HADS Scores for both Abnormal Anxiety &amp; Abnormal Depression at Week 4 and Week 12.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression</title>
          <description>Depression &amp; anxiety were measured by using the Hospital Anxiety &amp; Depression Scale (HADS).
The HADS was developed to assess anxiety &amp; depression. It is meant to differentiate symptoms of depression with those of anxiety.
Number of items: 14 (7 questions relating to anxiety; 7 questions relating to depression).
Responses are based on the relative frequency of symptoms over the past week, using a four point scale ranging from 0 (not at all) to 3 (very often indeed).
Responses are summed to provide separate scores for anxiety and depression symptomology with possible scores ranging from 0 to 21 for each scale.
The results presented below are the percentage of participants with abnormal HADS Scores for both Abnormal Anxiety &amp; Abnormal Depression at Week 4 and Week 12.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65"/>
                    <measurement group_id="O2" value="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13"/>
                    <measurement group_id="O2" value="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Mood</title>
        <description>Mood was measured by using the Profile of Mood States (POMS) questionnaire. The Profile of Moods States (POMS) is a 65-item multi-dimensional measure that provides a method of assessing transient, fluctuating active mood states. Key areas that are measured include: tension-anxiety, anger-hostility, fatigue-inertia, depression-dejection, vigor-activity, confusion-bewilderment. Responses to questions are scored with the following numerical values: Not at all = 1, A little = 2, Moderate = 3, Quite a bit = 4, Extremely = 5. A total score for a domain was obtained by summing the responses of individual items in the domain. The total POMS score can range from &quot;65&quot; to &quot;325.&quot; Each subject’s total POMS score at baseline and at Week 4 and Week 12 were used to calculate the percent of participants with less disturbance in mood at Week 4 and Week 12 compared to baseline. The percent of participants with less disturbance in mood is reported below.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Mood</title>
          <description>Mood was measured by using the Profile of Mood States (POMS) questionnaire. The Profile of Moods States (POMS) is a 65-item multi-dimensional measure that provides a method of assessing transient, fluctuating active mood states. Key areas that are measured include: tension-anxiety, anger-hostility, fatigue-inertia, depression-dejection, vigor-activity, confusion-bewilderment. Responses to questions are scored with the following numerical values: Not at all = 1, A little = 2, Moderate = 3, Quite a bit = 4, Extremely = 5. A total score for a domain was obtained by summing the responses of individual items in the domain. The total POMS score can range from &quot;65&quot; to &quot;325.&quot; Each subject’s total POMS score at baseline and at Week 4 and Week 12 were used to calculate the percent of participants with less disturbance in mood at Week 4 and Week 12 compared to baseline. The percent of participants with less disturbance in mood is reported below.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.40"/>
                    <measurement group_id="O2" value="42.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.16"/>
                    <measurement group_id="O2" value="44.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI Change From Baseline (kg/m2), Median</title>
        <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
Assessment of the effect of Brisdelle compared with placebo on body mass index.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>BMI Change From Baseline (kg/m2), Median</title>
          <description>Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.
Assessment of the effect of Brisdelle compared with placebo on body mass index.</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.17" upper_limit="2.66"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-3.08" upper_limit="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-2.33" upper_limit="2.10"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-2.56" upper_limit="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.</title>
        <description>Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.</title>
          <description>Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.
Weekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes</description>
          <population>The outcome data presented for these measurements were obtained using a scale questionnaire. Data were analyzed only from participants who completed and turned in the completed questionnaire. Therefore, the number of participants analyzed is not consistent with numbers provided in any of the rows in the participant flow module.</population>
          <units>Hot Flash Severity Score per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.525" spread="0.30"/>
                    <measurement group_id="O2" value="2.532" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.092" spread="0.24"/>
                    <measurement group_id="O2" value="-0.059" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0126" spread="0.31"/>
                    <measurement group_id="O2" value="-0.066" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0368</p_value>
            <p_value_desc>Week 4 severity</p_value_desc>
            <method>Rank transformed ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>Week 12 severity</p_value_desc>
            <method>Rank transformed ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
          <description>Experimental
Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Capsules</title>
          <description>Eligible subjects were randomized to receive either Brisdelle (paroxetine mesylate) Capsules or placebo capsules in a 1:1 ratio.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sciatic nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Lower extremity mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Circadian rhythm sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Elevated mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Self esteem decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sweat gland disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sailaja Bhaskar, Executive Director, Clinical Research</name_or_title>
      <organization>Noven Therapeutics, LLC</organization>
      <phone>(212) 287-0798</phone>
      <email>sbhaskar@noven.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

